34 results about "Aquaporin" patented technology

The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., diseases of water imbalance, for example edema (particularly edema of the brain and spinal cord, e.g., following trauma or ischemic stroke, as well as the edema associated with glioma, meningitis, acute mountain sickness, epileptic seizures, infections, metabolic disorders, hypoxia, water intoxication, hepatic failure, hepatic encephalopathy, diabetic ketoacidosis, abscess, eclampsia, Creutzfeldt-Jakob disease, and lupus cerebritis, as well as edema consequent to microgravity and / or radiation exposure, as well as edema consequent to invasive central nervous system procedures, e.g., neurosurgery, endovascular clot removal, spinal tap, aneurysm repair, or deep brain stimulation, as well as retinal edema), as well as hyponatremia and excess fluid retention, and diseases such as epilepsy, retinal ischemia and other diseases of the eye associated with abnormalities in intraocular pressure and / or tissue hydration, myocardial ischemia, myocardial ischemia / reperfusion injury, myocardial infarction, myocardial hypoxia, congestive heart failure, sepsis, and neuromyelitis optica, as well as migraines, as well as to novel assays for identifying aquaporin inhibitors.

The invention discloses bifidobacterium longum subsp. Infantis for regulating intestinal motility and aquaporin and application of the bifidobacterium longum subsp. Infantis, and belongs to the technical field of microorganisms. According to the invention, the bifidobacterium longum subsp. Infantis CCFM1269 is screened, and the bifidobacterium longum subsp. Infantis CCFM1269 has the effects of intestinal motility and aquaporin, specifically, the defecation frequency is reduced, and the water content of excrement and the small intestine propulsion rate are reduced. The intestinal motility abnormality is relieved by reducing the levels of neurotransmitters 5-HT, SP and VIP, and the intestinal moisture absorption and secretion are regulated by improving the mRNA expression of aquaporin AQP4 and AQP8. Meanwhile, the intestinal flora is adjusted by improving the diversity of the intestinal flora, and the content of propionic acid and butyric acid in excrement is increased.

This application relates to a pharmaceutical composition of an aquaporin inhibitor and a method for producing the same. The pharmaceutical composition comprises 2-((3,5-bis(trifluoromethyl)phenyl)carbamoyl)-4-chlorophenyl dihydrogen phosphate or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and meglumine. The pharmaceutical composition of an aquaporin inhibitor and a method for producing the same have the following advantages: the process is simple, easy to operate, conducive to industrial production, good product stability, and a significantly reduced content of degradable impurities, which ensures pharmaceutical efficacy.

The present invention relates to the therapeutic use of non-classical human major histocompatibility complex (MHC) molecules (also known as MHC class Ib molecules) in combination with a peptide antigen for the treatment of neuromyelitis optica (NMO). More specifically, the present invention relates to recombinant polypeptides comprising a peptide antigen in combination with one or more domains of a non-classical MHC class Ib molecule. The present invention also relates to methods of producing such recombinant polypeptides, pharmaceutical compositions comprising such recombinant polypeptides, and their use in the treatment of neuromyelitis optica (NMO).

To provide a compound which can be used for prevention, treatment and control of aquaporin-mediated conditions such as diseases of water imbalance, for example, cerebral edema, a pharmaceutical composition, and a method for producing the same.SOLUTION: There is provided a hydrate of 2 - {[3, 5-bis (trifluoromethyl) phenyl] carbamoyl} - 4-chlorophenyl dihydrogen phosphate represented by the following structure, which exhibits an XRPD pattern comprising at least five 2 θ (°) values selected from the group consisting of 8.8, 9.5, 11.1, 15.2, 15.5, 16.4, 20.2, 20.6, 23.6, 24.0, 24.9 and 27.2, wherein the XRPD is measured using an incident beam of CuK α radiation of 1.54059 Å.SELECTED DRAWING: None

The invention discloses a dampness-clearing sleep-aiding Tibetan foot bathing tablet and a preparation method thereof, and relates to the technical field of traditional Chinese medicine preparations, the dampness-clearing sleep-aiding Tibetan foot bathing tablet is composed of a monarch drug group, a ministerial drug group, an adjuvant drug group, a conductant drug group and an auxiliary material group, and the preparation method comprises the following steps: step 1, crushing; step 2, weighing; step 3, extracting active ingredients; step 4, drying and powdering; step 5, total mixing; step 6, tabletting; step 7, inner packaging; and step 8, external packaging. Through the compatibility of monarch, minister, assistant and guide, the synergistic effect of dampness clearing and sleep aiding is realized, the monarch drug group and the adjuvant drug group synergistically regulate a dampness clearing pathway (AQP4 aquaporin + TRPV1 ion channel), the minister drug group and the guide drug group synergistically enhance the sleep aiding effect (GABA receptor activation + glutamic acid inhibition), and clinical experiments show that after the traditional Chinese medicine composition is used for 4 weeks, the effective rate of improving the dampness symptom reaches 80%, and the curative effect is good. And the sleep quality improvement rate reaches 82%.

The application belongs to the technical field of microorganisms, and provides application of Propionibacterium freudenreichii subsp. shermanii in preparation of products for improving constipation and depression, wherein the Propionibacterium freudenreichii subsp. shermanii NHNK-616 is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number is CCTCC NO: M 20241429. The inventors find that NHNK-616 has the functions of promoting 5-HT secretion, up-regulating intestinal aquaporin and brain-derived neurotrophic factor genes, metabolically producing gamma-aminobutyric acid, inhibiting growth of Candida albicans, inhibiting hypha formation of Candida albicans, combining with hypha of Candida albicans, and up-regulating expression of intestinal defensin and mucin genes, and therefore can be used for preparing products for improving constipation and depression.

The invention relates to a bacteriostatic repair medical gel containing glycosylglycerol and a preparation method thereof, and belongs to the technical field of medical dressings. The gel is prepared by taking glycosylglycerol as a main active component and cooperating with chitosan, collagen, a silver ion antibacterial agent and other components through a specific process. The gel has triple synergistic effects: glycosylglycerol enhances the skin barrier function and provides lasting moisture retention by activating aquaporin; chitosan and silver ions provide broad-spectrum antibacterial activity; and collagen and glucan promote tissue repair and cell proliferation. Experiments show that the antibacterial rate of the gel on common pathogenic bacteria such as staphylococcus aureus and escherichia coli exceeds 99.9%, meanwhile, the wound healing speed can be increased by 40% or above, and the gel is good in biocompatibility and free of skin irritation. The gel can be used for repairing and nursing various skin injuries such as burn wounds, chronic ulcers and surgical wounds.

The application belongs to the technical field of microorganisms, and discloses a propionic acid-producing propionic acid bacteria NHNK-621 and application of the propionic acid bacteria in preparation of products for improving constipation and memory, the bacteria strain has been preserved in the China Center for Type Culture Collection on November 25, 2024, and the number is CCTCC NO: M 20242631. The propionic acid bacteria NHNK-621 provided by the application has the functions of promoting 5-HT secretion, up-regulating intestinal aquaporin and brain-derived neurotrophic factor genes, metabolically producing gamma-aminobutyric acid, inhibiting growth of Candida albicans, inhibiting hypha formation of Candida albicans, combining with hypha of Candida albicans, up-regulating intestinal defensin and mucin gene expression, in addition, the bacterial biofilm can increase the colonization ability to intestinal epithelial cells, and can be used for preparing products for improving constipation and memory.

The application discloses a two-compartment modeling and prediction method for sodium kinetics in hemodialysis. The method divides the patient's body fluid into two compartments of extracellular fluid and intracellular fluid, and establishes a coupled differential equation set to describe the sodium transfer kinetics in the dialysis process. The application corrects the physical error of the existing model in the dispersion equilibrium concentration formula, proposes C_eq=[Na]d / σ (σ=0.97 is the Gibbs-Donnan factor) to replace the traditional Donnan formula and the old recommended formula, eliminates the false dispersion gradient under the condition of isonatric dialysis based on the physical fact that electrolytes are only distributed in the plasma water phase, and removes the error solvent drag term by clearly defining the biophysical constraints of the cell membrane aquaporin not transporting sodium. The application adopts a perturbation reference model to replace the traditional Fick diffusion law to describe the cell membrane sodium exchange, and more accurately reflects the intracellular and extracellular sodium kinetics. The model can accurately predict the serum sodium change and sodium removal under different dialysis prescriptions, and can generate a sodium removal contour map for clinical prescription optimization.

The invention discloses application of leuconostoc mesenteroides subsp. Mesenteroides in improvement of constipation and depression, and belongs to the technical field of marine microorganisms. The invention discloses a leuconostoc mesenteroides subsp. Mesenteroides NHNK-613, which is preserved in the China Center for Type Culture Collection on July 1, 2024, and the preservation number of the leuconostoc mesenteroides subsp. Mesenteroides NHNK-613 is CCTCC (China Center for Type Culture Collection) NO: M 20241431. The NHNK-613 has the functions of promoting 5-HT secretion, up-regulating intestinal aquaporin and brain-derived neurotrophic factor genes, metabolizing to generate gamma-aminobutyric acid, inhibiting the growth of candida albicans, inhibiting the formation of candida albicans filaments, combining the candida albicans filaments and up-regulating intestinal defensin and mucoprotein gene expression; the traditional Chinese medicine composition can be used for preparing products for improving constipation and depression.

The invention relates to the technical field of beauty skin care products, in particular to a glutamic acid derivative, a preparation method and application of the glutamic acid derivative in skin care products. The invention provides a compound with a structure as shown in a formula (I), which not only has rhythm protein up-regulation expression and oxidation resistance, but also has a good effect on up-regulation of aquaporin expression, silk protein expression and hypoxia inducible factor expression. The potential application prospects are realized on the effects of moisturizing the skin, repairing the barrier, promoting the ruddy skin and the like.

The invention discloses a germplasm aquaporin OsPIP2 and a preparation method thereof. 1 is applied to regulation and control of rice chalkiness, and belongs to the technical field of biological breeding. According to the invention, a gene OsPIP2 for controlling chalkiness of rice is cloned; 1, the nucleotide sequence of the gene is as shown in SEQ ID NO. 1. According to the invention, a gene editing technology Crispr / cas9 is used for modifying OsPIP2 in wild type ZH11; after the function of the rice chalkiness gene OsPIP2 is destroyed, knockout strains show that the chalkiness rate and the chalkiness degree of rice grains are remarkably improved, which indicates that the gene has the function of regulating and controlling rice chalkiness, and meanwhile, analysis finds that the rice chalkiness gene OsPIP2 is a japonica rice type OsPIP2; the chalkiness of 1Hap3 is obviously lower than that of other haplotypes, which indicates that OsPIP2; the 1Hap3 has the potential of reducing chalkiness of indica rice, gene resources can be provided for high-quality breeding of rice, and reference is provided for functional research of other homologous genes.

The invention discloses bifidobacterium breve for regulating intestinal motility and aquaporin and application of the bifidobacterium breve, and belongs to the technical field of microorganisms. According to the invention, a strain of bifidobacterium breve CCFM1078 is screened out, and the bifidobacterium breve CCFM1078 has the effect of regulating intestinal motility and aquaporin, specifically, the defecation frequency is reduced, and the water content of excrement and the small intestine propulsion rate are reduced. The intestinal motility abnormality is relieved by reducing the levels of neurotransmitters 5-HT, SP and VIP, and the intestinal moisture absorption and secretion are regulated by improving the mRNA expression of aquaporin AQP3, AQP4 and AQP8. Meanwhile, the intestinal flora is adjusted by improving the diversity of the intestinal flora, and the content of propionic acid and butyric acid in excrement is increased.

The invention discloses a vacuolar aquaporin OsTIP1 and a preparation method of the vacuolar aquaporin OsTIP1. The invention discloses application of 2 in regulation and control of rice quality and belongs to the technical field of biological breeding. According to the invention, a vacuolar aquaporin family gene OsTIP1 for controlling rice quality is cloned; 2, the nucleotide sequence of the gene is as shown in SEQ ID NO. 1. According to the invention, a CRISPR / Cas9 gene editing technology is used for editing the gene OsTIP1 in wild type rice; after OsTIP1 and OsTIP2 are knocked out, the chalky grain rate of transgenic line grains is remarkably increased compared with that of wild type grains, it is indicated that the gene participates in and regulates chalky formation and has the function of regulating the rice quality, and meanwhile it is found through analysis that OsTIP1; the chalkiness of 2Hap4 is obviously lower than that of other haplotypes, and the gene can be used for breeding high-quality varieties of cereal crops such as rice and the like, and also provides reference for cloning and research of homologous genes in other species.

The present invention relates to delivering benefits related to maintaining a resilient microbiome on skin through a personal care composition, especially through wash off compositions like soap, body wash or shampoo. This is achieved by using starch or its microbial metabolite preferably in such compositions. It works by upregulating expression levels of Aquaporin-3, Claudin 1, Keratin- 4, Filaggrin- 1 or Desmoglein 1 on skin.

The invention provides a method for synergistically regulating cotton fiber elongation and verticillium wilt resistance based on an upland cotton GhMP gene and a transgenic cotton plant, and relates to the technical field of genetic engineering. The gene encodes a membrane protein, and overexpression and RNA interference transgenic line experiments prove that the expression level of GhMP is positively correlated with fiber development and disease resistance: the fiber length can be significantly increased and the verticillium wilt resistance can be improved by expression increase, and the fiber shortening and the resistance weakening can be caused by expression reduction. A further research shows that the GhMP protein is positioned on a cell membrane, can interact with GhPIP2.7 and GhTIP1.1 aquaporin, and jointly participates in hydrogen peroxide transmembrane transport to form a molecular compound for regulating and controlling fiber elongation and preventing diseases. The invention provides a key target gene with both quality improvement and disease resistance enhancement, provides a new strategy and gene resources for cotton multi-trait molecular breeding, and has important application value and popularization prospect.

The present disclosure relates to a cosmetic composition containing an extract of Cyperus rotundus extracted using warm microbubbles. The extract inhibits nitric oxide (NO) production and exhibits excellent anti-inflammatory efficacy by inhibiting the expression of interleukin 6 (IL-6), cyclooxygenase-2 (COX-2), interleukin-1β (IL-1β), and tumor necrosis factor-α (TNF-α), which are inflammatory expression factors. In addition, the extract enhances the expression of aquaporin-3 (AQP-3), hyaluronan synthase 2 (HAS-2), claudin-1 (CLDN-1), cadherin 1 (CDH1), filaggrin (FLG), and involucrin (IVL), which are genes related to the skin barrier and moisturizing. Thus, when using the extract for cosmetic products, excellent effects can be exhibited in skin soothing, moisturizing, enhancement of the skin barrier, relief of irritation such as erythema, relief of pruritus, and the like, so the extract can be usefully applied to multi-care products that improve skin conditions.

The invention belongs to the field of biological medicine, and discloses a pharmaceutical composition combining an aquaporin inhibitor and temozolomide for treating brain glioma, and the pharmaceutical composition comprises an AQP4 inhibitor AER270 and TMZ. The invention further discloses a pharmaceutical preparation containing the pharmaceutical composition and application of the pharmaceutical preparation to preparation of drugs for treating brain glioma. The composition provided by the invention provides an effective drug combination strategy for treatment of brain glioma, and it is found for the first time that the combination of AER270 and TMZ has a synergistic effect on treatment of brain glioma.

The invention belongs to the field of biological medicine, and discloses a pharmaceutical composition combining an aquaporin inhibitor and amphotericin B for treating brain glioma, and the pharmaceutical composition comprises an AQP4 inhibitor AER-270 and amphotericin B. The invention further discloses a pharmaceutical preparation containing the pharmaceutical composition and application of the pharmaceutical preparation to preparation of drugs for treating brain glioma. The tumor cell inhibition effect of the pharmaceutical composition provided by the invention is obviously better than that of single AER270 or amphotericin B, the pharmaceutical composition has an obvious synergistic effect, and an effective drug combination strategy is provided for treatment of brain glioma.

This invention relates to methods and compositions for detecting, diagnosing, preventing, treating or ameliorating the symptoms of a demyelinating condition selected from: enterotoxemia (ET), multiple sclerosis (MS), clinically definite MS (CDMS), clinically isolated syndrome (CIS), neuromyelitis optica spectrum disorder (NMOSD), optic neuritis (ON), neuromyelitis optica (NMO), myelitis, myelitis, transverse myelitis (TM), a disease or condition characterised by the increase or presence of antibodies against aquaporin-4 (AQP-4) and / or astrocyte damage, and acute disseminated encephalomyelitis (ADEM) in a human or animal subject in need. The methods comprise administering to the subject a composition comprising an effective amount of an agent that directly or indirectly interferes with epsilon toxin (ETX) produced by Clostridium perfringens type B or type D bacterial strain, an ETX-binding receptor, or an interaction of ETX with its binding receptor so as to inhibit or suppress ETX modulated receptor signalling activities. The invention also provides novel polypeptides useful as a vaccine against diseases caused by or associated with the epsilon toxin of Clostridium perfringens.

This invention provides a method based on upland cotton GhMP This research relates to the field of genetic engineering technology and describes a method for the coordinated regulation of cotton fiber elongation and Verticillium wilt resistance using genes, as well as transgenic cotton plants. The gene encodes a membrane protein, and experiments using overexpression and RNA interference transgenic lines have demonstrated its effectiveness. GhMP The expression level of this compound is positively correlated with fiber development and disease resistance: increased expression significantly increases fiber length and improves resistance to Verticillium wilt, while decreased expression leads to fiber shortening and weakened resistance. Further studies have shown that... GhMP Proteins are located on the cell membrane and can interact with... GhPIP2.7 and GhTIP1.1 Aquaporins interact and jointly participate in the transmembrane transport of hydrogen peroxide, forming a molecular complex that regulates fiber elongation and disease resistance. This invention provides a key target gene that combines quality improvement and disease resistance enhancement, offering a new strategy and gene resource for multi-trait molecular breeding of cotton, and has significant application value and promising prospects.

The invention belongs to the field of biological medicine, and discloses a pharmaceutical composition combining an aquaporin inhibitor and an oxidative phosphorylation inhibitor for treating brain glioma, and the pharmaceutical composition comprises an AQP4 inhibitor AER-270 and an oxidative phosphorylation inhibitor Gboxin. The invention further discloses a pharmaceutical preparation containing the pharmaceutical composition and application of the pharmaceutical preparation to preparation of drugs for treating brain glioma. According to the composition provided by the invention, through combined administration of the AER270 and the Gboxin, the inhibition effect on the brain glioma is obviously better than that of single AER270 or single Gboxin, the combination of the AER270 and the Gboxin has a synergistic effect on treatment of the brain glioma, and an effective drug combination strategy is provided for treatment of the brain glioma.

The present invention relates to methods of modulating magnesium ion uptake and transport in plants. Specifically, a method of modulating magnesium ion uptake and transport in plants, ameliorating conditions caused by magnesium deficiency or excess in plants, or modulating plant growth, comprising modulating the expression or activity of aquaporins is provided. Aquaporins have been found for the first time to have a function in Mg 2+ uptake and transport.

The invention belongs to the technical field of microorganisms, and discloses a propionibacterium NHNK-621 capable of producing propionate and application of the propionibacterium NHNK-621 in preparation of products for improving constipation and memory, the propionibacterium NHNK-621 is preserved in China Center for Type Culture Collection on November 25, 2024, and the serial number of the propionibacterium NHNK-621 is CCTCC NO: M 20242631. The propionibacterium NHNK-621 has the functions of promoting 5-HT secretion, up-regulating intestinal aquaporin and brain-derived neurotrophic factor genes, metabolizing to generate gamma-aminobutyric acid, inhibiting the growth of candida albicans, inhibiting the formation of candida albicans hypha, combining with the candida albicans hypha, up-regulating intestinal defensin and mucoprotein gene expression, and can be used for preparing the propionibacterium. In addition, the bacterial biofilm can increase the colonization ability to intestinal epithelial cells, and can be used for preparing products for improving constipation and memory.

This invention discloses a small basic membrane intrinsic protein TtSIP1;2 of mitochondrial aquaporin and its encoding gene. TtSIP1; 2 Its cDNA reading frame sequence is shown in SEQ ID NO.2, and the encoded amino acid sequence is shown in SEQ ID NO.1. This invention... TtSIP1;2 The gene-encoded protein TtSIP1;2 is associated with the tolerance of Saccharomyces cerevisiae to high salt, high osmotic pressure (simulated drought), high temperature, and H2O2 (oxidative stress). TtSIP1;2 The gene can enhance yeast's tolerance to various abiotic stresses, improve its survival rate under stress, and promote yeast vitality. Overexpression of this gene in Arabidopsis thaliana can improve the salt and drought tolerance of transgenic plants. This invention... TtSIP1;2 Genes can be applied to the genetic improvement of stress tolerance in engineered bacteria and plants, and can be used to cultivate transgenic engineered bacteria or plant varieties with improved tolerance to high salt, drought, high temperature and oxidative stress.

The invention discloses a mulberry aquaporin coding gene and application thereof. The nucleotide sequence of the coding gene is shown as SEQ ID NO. 1. According to the invention, the aquaporin MnPIP1 is cloned in a woody plant mulberry; 2 genes, the expression of the gene is obviously up-regulated in the process of infecting mulberry trees by bacterial wilt, and the gene is a key factor for responding infection by ralstonia solanacearum. According to the invention, mulberry MnPIP1 is silenced through a virus-induced gene silencing technology; the disease resistance of the plant to ralstonia solanacearum is obviously enhanced, which shows that the infection speed of pathogenic bacteria is slowed down, and the disease index is reduced. The invention discloses MnPIP1 for the first time; the invention provides a novel theoretical basis and a potential target gene for mulberry disease-resistant breeding by virtue of a molecular regulation mechanism of 2 in mulberry bacterial wilt resistance, and is expected to improve the disease resistance of plants, so that the purposes of increasing the yield and reducing the pesticide are achieved, and the application prospect is important.

The invention relates to the field of cosmetics, in particular to a sialic acid composition with the effects of tightening, fading wrinkles and brightening the skin color and cosmetics. The invention relates to a sialic acid composition with the effects of tightening, fading wrinkles and brightening skin. The sialic acid composition comprises a saussurea extract and sialic acid, in the sialic acid composition, the mass ratio of sialic acid to the abelmoschus esculentus extract is (0.5: 1)-(1: 2.5). In the sialic acid composition, the mass ratio of sialic acid to the millettia extract is 0.5: 1-1: 2.5, the sialic acid and the millettia extract can form a stable synergistic effect system under the ratio, and the effect of the sialic acid composition is obviously superior to that of a single component or combination of other ratios. By activating skin cell AQP3 aquaporin, water permeation is enhanced, and the synthesis efficiency of fibroblast collagen I is improved in a targeted manner; the anti-aging and firming effects and the skin color brightening effects of the composition are improved.

The invention discloses a sicca syndrome marker HMGB1 and application thereof, belongs to the field of biological medicine, and particularly relates to application of sicca syndrome marker high-mobility group protein B1 in diagnosis and treatment of sicca syndrome. The invention discloses that the expression of HMGB1 in salivary gland tissues of SS patients is obviously increased, the transcriptional level of key aquaporin AQP5 related to salivary secretion is obviously reduced, and the expression of HMGB1 is in negative correlation with the expression of AQP5. The invention also discloses application of the glycyrrhizin to inhibition of transcription or expression of the HMGB1 gene, and the glycyrrhizin is used as a sicca syndrome treatment preparation. The invention provides a potential new target for diagnosis and treatment of sicca syndrome, and has important clinical application value.